

Translational Toxicology: Data Visualisation Across Phases

Webinar: 12 May 2020 Presented by Aishling Cooke and Matt Segall

> © 2020 Optibrium Ltd. . Optibrium™, StarDrop™, Auto-Modeller™, Card View™, Glowing Molecule™ and Augmented Chemistry™ are trademarks of Optibrium Ltd

Today's Webinar Presenters





Aishling Cooke Senior Software Engineer Optibrium



Matt Segall CEO Optibrium

Introduction

- What is eTRANSAFE?
- What should a visualisation application for the system do?
 - End-user requirements
 - \circ Data sources
- Current version
- Challenges & future directions


What is eTRANSAFE?

"The eTRANSAFE (Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management) project works to improve the efficiency of translational safety assessment approaches during the medicines discovery pipeline"

- Funded by the Innovative Medicines Initiative (IMI)
- Public-private partnership
- 27 partners
 - \circ Academic institutions
 - \circ SMEs
 - EFPIA partners









Allow translational comparison between pre-clinical and clinical toxicology data, facilitating research and revealing interesting patterns

eTRANSAFE System & the Visualisation Application



Where Should We Start?




What types of data will be in the system?


What functionality would be useful for our end-users?


Data

Pre-Clinical	Clinical	Other
SEND studies	Studies	Target
	Post-marketing	Off-target
		Molecule properties




Initial Designs






Data structure




Ontology Mapping



Demo of Current Version






Challenges


- Complex dependencies
 - Software dependencies & timelines
- Data complexity and diversity
- Extensible vs specialised

THESE CHARTS SHOW MOVIE CHARACTER INTERACTIONS. THE HORIZONTAL AXIS IS TIME. THE VERTICAL GROUPING OF THE LINES INDICATES WHICH CHARACTERS ARE TOGETHER AT A GIVEN TIME.



https://xkcd.com/657/

- Single study
 - \circ Table
 - \circ Charts
- Summary level
 - More chart types (e.g. chemical space)
 - Better use of variables (e.g. frequency)
 - Further customisation
- Useful incorporation of new data sources of different types



SEND Pivot Table

TUDYID DOMAIN DS2014 BG	PDS2014-C		CD BGTEST B N Body Wei⊧		BGORRESL BGSTRESC g 31.6			BGSTAT	3GREASINE BO	JEXCLEL	. BGREAS	SEX BGDTC 2010-12-0 2			BGEND	<u>)Y</u>								
	PDS2014-C		N Body Weig		-		_					2010-12-0 2			1	2								
52014 BG	PDS2014-C		N Body Weig		•		-					2010-12-1				2								
	PDS2014-C		N Body Weig	-	-							2010-12-1			2	3								
0S2014 BG 0S2014 BG	PDS2014-C	4 BWGAIN 5 BWGAIN			ึ้ บรบBJID รบBJID		TC RFENDT	TC SITEID	BRTHDTC	J AGE	AGET			SPECIE		TRAIN SBSTRAI	AIN ARMCD	CD ARM S	SETCD					
DS2014 BG DS2014 BG	PDS2014-C	6 BWGAIN	N BC					4##			0	DAYS	м	RAT	SP'	PRAGUE-DAWLEY	_Y	1 M - Vehicle	. 1	<u>_</u> 1				
DS2014 BG	PDS2014-C	7 BWGAIN	000014	.4 DM	PDS2014-0	2 ######	***	###			0	DAYS	м	RAT	SP'	PRAGUE-DAWLEY	_Y	1 M - Vehicle	4 1	1				
DS2014 BG DS2014 BG	PDS2014-C	8 BWGAIN	000014	.4 DM	PDS2014-C	3 ######		4##			0	DAYS	м	RAT	SP'	PRAGUE-DAWLEY	Y	1 M - Vehicle	4 1	1				
DS2014 BG	PDS2014-C	9 BWGAIN	N BC		PDS2014-0	4 ######		4##			0	DAYS	м	RAT	SP'	PRAGUE-DAWLEY	_Y	1 M - Vehicle	(1	<u>,</u>				
DS2014 BG	PDS2014-C	10 BWGAIN	000014	4 DM	PDS2014-0	5 ######		###			0	DAYS	м	RAT	SP'	PRAGUE-DAWLEY	.Y	1 M - Vehicle	(1					
DS2014 BG	PDS2014-C	11 BWGAIN	0002014	4 DM	PDS2014-C	6 ######		###			0	DAYS	м	RAT	SP'	PRAGUE-DAWLEY	_Y	1 M - Vehicle	. 1					
DS2014 BG	PDS2014-C		000014	4 DM					014550 0	MATESTO				COMCTORS								ALAT		
DS2014 BG	PDS2014-C	12 BWGAIN 13 BWGAIN			PDS2014-C			USUBJID O			C OMTEST					TRES OMSTRES (OMSTAT			MANTRE OMSPCCN ON	ASPCUP UN	JLAI		
052014 BG 052014 BG	PDS2014-C	13 BWGAIN 14 BWGAIN	N BC		PDS2014-C	PDS2014 C		PDS2014-0		NEIGHT		-	-	2.0789		0789 g		BRAI						
DS2014 BG	PDS2014-C	14 BWGAIN 15 BWGAIN			PDS2014-0	PDS2014 C		PDS2014-		NEIGHT	_		-	1.3104		3104 g		HEAI						
		15 BWGAIN 16 BWGAIN	N DC DDC2014		PDS2014-C	PDS2014 0		PDS2014-		NEIGHT			•	8.7775		7775 g		LIVE						
DS2014 BG	PDS2014-C	16 BWGAIN 17 BWGAIN	N BC DDC2044		PDS2014-0	PDS2014 C		PDS2014-0		NEIGHT				3.2055		2055 g			ONEY					
DS2014 BG	PDS2014-0		N BC		PDS2014-0	PDS2014 0		PDS2014-		NEIGHT	-		•	4.069		.069 g			STIS					
DS2014 BG	PDS2014-0	18 BWGAIN	N DC DDC2014		PDS2014-C	PDS2014 C		PDS2014-0		NEIGHT				0.0148		0148 g			AND PI	FIXED				
DS2014 BG	PDS2014-C	19 BWGAIN	N DC		PDS2014-0	PDS2014 0		PDS2014-	C	STUDYID		IAIN USUBJID				GRPID PPTESTCD	D PPTEST				PPSTRESC	PPSTRESN PPSTRESU PPST	TAT PPREASND PPSPEC	C VISITDY P
DS2014 BG	PDS2014-C		N DC		PDS2014-C	PDS2014 0		PDS2014-0	8 V p	PDS2014	14 PP	PDS2014-			1	CMAX		onc PDS-12345678		1670 ng/mL	1670		PLASMA	
DS2014 BG	PDS2014-0	21 BWGAIN	N DC DDC2014		PDS2014-C	PDS2014 0		PDS2014-		DDS2014	14 DD	PDS2014-			2	TMAX		f CN PDS-12345678		2 h	2	2 h	PLASMA	
DS2014 BG	PDS2014-C	22 BWGAIN	N DC		PDS2014-0	PDS2014 C		PDS2014-0	10 V P	PDS2014	14 PP	PDS2014-			3	TLST		f La PDS-12345678		7 h	7	7 h	PLASMA	
DS2014 BG	PDS2014-C	23 BWGAIN	N DU DDOOOAAA		PDS2014-0	PDS2014 C		PDS2014-0	11 V D	PDS2014	14 DD	PDS2014-			4			ver PDS-1234567		11126 h*ng/mL	11126		PLASMA	
PDS2014 BG	PDS2014-C	24 BWGAIN	N DC		PDS2014-0	PDS2014 C		PDS2014-0	12 V p	PDS2014	14 PP	PDS2014-			5	AUCLST		La: PDS-1234567		8348 h*ng/mL	8348		PLASMA	
PDS2014 BG	PDS2014-0	25 BWGAIN	N DC		PDS2014-0	PDS2014 C		PDS2014-0	13 V P	PDS2014	14 PP	PDS2014-			6			finit PDS-12345678		-11177 h*ng/mL	-11177		PLASMA	
PDS2014 BG	PDS2014-C	26 BWGAIN	V DU DDOODAAA		PDS2014-0	PDS2014 C		PDS2014-0	14 V D	DDS2014	14 DD	PDS2014-			7	CMAX		onc PDS-1234567		1410 ng/mL	1410		PLASMA	
PDS2014 BG	PDS2014-C	27 BWGAIN	0000014		PDS2014-0	PDS2014 C		PDS2014-0	13 V p	PDS2014	14 PP	PDS2014-			8	TMAX		f CN PDS-12345678		2 h	2	2 h	PLASMA	
PDS2014 BG	PDS2014-0	28 BWGAIN	PDS2014		PDS2014-0	PDS2014 C		PDS2014-0	10 0	PDS2014	14 DD	PDS2014-			9	TLST		f La PDS-1234567		7 h	7	7 h	PLASMA	
			PDS2014		PDS2014-0	PDS2014 C		PDS2014-0	1/ V D	DDS2014	1/1 DD	PDS2014-			10			ver PDS-12345678		6888 h*ng/mL	6888		PLASMA	
			PDS2014		PDS2014-0	PDS2014 C		PDS2014-0	10 V p	PDS2014	14 PP	PDS2014-			11	AUCLST		La: PDS-12345678		5222 h*ng/mL	5222		PLASMA	
			PDS2014		PDS2014-0			PDS2014-0	1. P	DDS2014	14 DD	PDS2014-			12	CMAX		onc PDS-12345678		2140 ng/mL	2140	-	PLASMA	
			PDS2014 PDS2014		PDS2014-0	PDS2014 0		PDS2014-0	20 V p	PDS2014	14 PP	PDS2014-			13	TMAX		f CN PDS-12345678		2 h	2140	2 h	PLASMA	
			LD25014		PDS2014-Q	PDS2014 C	OM F	PDS2014-0	21 V D	PDS2014	14 PP	PDS2014-			14	TLST		f La PDS-12345678		7 h	7	7 h	PLASMA	
					<i>r</i>	PDS2014 C	OM ′	PDS2014-0	22 V p	PDS2014	14 PP	PDS2014-			15			ver PDS-12345678		-23450 h*ng/mL	-23450		PLASMA	
					F	PDS2014 C	OM	PDS2014-0	23 V P	PDS2014	14 PP	PD32014-			15	AUCLST		La: PDS-12345678		12724 h*ng/mL	12724	-	PLASMA	
					r	PDS2014 C	OM (PDS2014-	24 V D	PDS2014	14 DD	PD32014-			10	AUCIFO		finit PDS-12345678		-25088 h*ng/mL	-25088	~	PLASMA	
					r	PDS2014 0	OM	PDS2014-0	25 V	PDS2014	I DD	PDS2014-			18	CMAX		onc PDS-12345678		2380 ng/mL	2380		PLASMA	
					J.	PDS2014 0	OM	PDS2014-0	26 V	PDS2014	14 DD	PDS2014-			18	TMAX		f CN PDS-12345678		2380 lig/iiiL 2 h	2300	2380 hg/mL 2 h	PLASMA	
						PDS2014 0	OM	PDS2014-0	27 V	PDS2014	14 DD	PDS2014-			20	TLST		f La PDS-12345678		2 h 24 h	24		PLASMA	
						PDS2014 0	OM	PDS2014-0	28 V	PDS2014	14 DD	PDS2014-			20			/er PDS-12345678		14883 h*ng/mL	14883		PLASMA	
																					14883	~		
										PDS2014		PDS2014-			22			La: PDS-12345678		14883 h*ng/mL		~	PLASMA	
										PDS2014		PDS2014-			23	CMAX		onc PDS-12345678		2640 ng/mL	2640		PLASMA	
										PDS2014		PDS2014-			24	TMAX		f CN PDS-12345678		4 h	4	4 h	PLASMA	
										PDS2014		PDS2014-			25	TLST		f La PDS-12345678		24 h	24		PLASMA	
										PDS2014		PDS2014-			26			ver PDS-12345678		20786 h*ng/mL	20786		PLASMA	
										PDS2014		PDS2014-			27			La: PDS-12345678		20786 h*ng/mL	20786	~	PLASMA	
									P'	PDS2014	.4 PP	PDS2014-	-0033	^	28	AUCIFO	AUC Infir	finit PDS-12345678	/8	21126 h*ng/mL	21126	21126 h*ng/mL	PLASMA	/A 1

Categorical Domain (e.g. MI)

		Treatment										
		Study Day	30									
		Animal ID	PDS2014	. P								
		<										>
Test	Tissue											
	ARTERY AORTA	-	NORMAL	N								
	BONE MARROW FEMUR		Fat vacuol	. F								
	BONE MARROW STERNUM		NORMAL	٨								
	BONE STERNUM		NORMAL	٢								
	BRAIN		NORMAL	٢								
	CERVIX		NULL	NULL	NULL	NULL	NULL	NORMAL	NORMAL	NORMAL	NORMAL	٢
	EPIDIDYMIS		NORMAL	NORMAL	NORMAL	NORMAL	NORMAL	NULL	NULL	NULL	NULL	٢
	ESOPHAGUS		NORMAL	١								
	EYE		NORMAL	١								
	GLAND ADRENAL		NORMAL	P								
	GLAND COAGULATING		NORMAL	NORMAL	NORMAL	NORMAL	NORMAL	NULL	NULL	NULL	NULL	٢
	GLAND HARDERIAN		NORMAL	٢								
	GLAND MAMMARY		NORMAL	٢								
	GLAND PARATHYROID		NORMAL	٢								
	GLAND PITUITARY		NORMAL	٢								
	GLAND PROSTATE		Inflammati	Inflammati	Inflammati	Inflammati	Inflammati	NULL	NULL	NULL	NULL	١

Categorical Domain (e.g. MI)

		Treatment		Control		Test				
		Study Day	30	31	58	30	31	58		
Test	Tissue									
	ARTERY AORTA		0/10	0/10	NULL	0/10	0/10	NULL		
	BONE MARROW FEMUR		7/10	6/10	NULL	7/10	7/10	NULL		
	BONE MARROW STERNUM		0/10	0/10	0/10	1/29	0/30	0/10		
	BONE STERNUM		0/10	0/10	0/10	0/29	0/30	0/10		
	BRAIN		0/10	0/10	NULL	0/10	0/10	NULL		
	CERVIX		0/5	0/5	NORMAL	0/5	0/10	0/2		
	EPIDIDYMIS		0/5	0/5	NULL	0/5	0/5	NORMAL		
	ESOPHAGUS		0/10	0/10	NULL	0/10	0/10	NULL		
	EYE		1/10	0/10	NULL	1/10	0/10	NULL		
	GLAND ADRENAL		0/10	1/10	3/10	15/30	17/30	3/10		
	GLAND COAGULATING		0/5	0/5	NULL	0/5	0/5	NULL		
	GLAND HARDERIAN		0/10	0/10	NULL	1/10	0/10	NULL		
	GLAND MAMMARY		0/10	0/9	0/5	7/20	3/20	0/5		
	GLAND PARATHYROID		0/10	0/10	NULL	0/9	0/10	NULL		
	GLAND PITUITARY		1/10	0/10	NULL	0/10	0/10	NULL		
	GLAND PROSTATE		2/5	3/5	NULL	4/5	2/5	NULL		

Numerical Domain (e.g. BW)

		Treatment										
		_										_
		Sex										F
		Animal ID	PDS2014	PDS2014	PDS2014	. P						
		<										>
Test	Study Day											
	-4		299.9	299.9	299.9	299.9	299.9	299.9	299.9	299.9	299.9	2
	1		331.5	331.5	331.5	331.5	331.5	331.5	331.5	331.5	331.5	3
	10		375.6	375.6	375.6	375.6	375.6	375.6	375.6	375.6	375.6	3
	11		384.9	384.9	384.9	384.9	384.9	384.9	384.9	384.9	384.9	3
	12		387.3	387.3	387.3	387.3	387.3	387.3	387.3	387.3	387.3	3
	13		397.6	397.6	397.6	397.6	397.6	397.6	397 . 6	397.6	397.6	3
	14		397.8	397.8	397.8	397.8	397.8	397.8	397.8	397.8	397.8	з
	15		402.6	402.6	402.6	402.6	402.6	402.6	402.6	402.6	402.6	4
	16		404.5	404.5	404.5	404.5	404.5	404.5	404.5	404.5	404.5	4
	17		413.5	413.5	413.5	413.5	413.5	413.5	413.5	413.5	413.5	4
	18		415.9	415.9	415.9	415.9	415.9	415.9	415.9	415.9	415.9	4
	19		420.5	420.5	420.5	420.5	420.5	420.5	420.5	420.5	420.5	4
	2		333.3	333.3	333.3	333.3	333.3	333.3	333.3	333.3	333.3	3
	20		424.5	424.5	424.5	424.5	424.5	424.5	424.5	424.5	424.5	4
	21		427.8	427.8	427.8	427.8	427.8	427.8	427.8	427.8	427.8	4
	22		434.9	434.9	434.9	434.9	434.9	434.9	434.9	434.9	434.9	4
		<										>

Numerical Domain (e.g. BW)

		Treatment	Control	Test
Test	Study Day			^
-	-4		231.953	231.827
_	1		251.881	255.234
_	10		291.311	270.376
	11		299.486	276.05
	12		298.817	273.392
	13		306.157	278.344
	14		308.577	280.064
	15		310.883	280.98
	16		315.383	286.693
	17		320.397	289.689
	18		320.9	290.209
	19		326.477	293.184
	2		254.98	249.182
	20		330.317	294.826
	21		329.129	298.685
	22		335.151	301.903
		<		×

Thank you for joining us for today's webinar

For further information please contact: info@optibrium.com

A recording of the presentation will be made available on the Optibrium Community website:

optibrium.com/community



